Thailand Medical Cannabis Export to the UK: The Import Route for Licensed Buyers
UPDATED: AUGUST 10, 2026
The United Kingdom is now one of the fastest-growing medical cannabis import markets in the world, and the door into it is narrower than most exporters assume. There is no direct route from a foreign farm to a UK pharmacy. This guide sets out who holds which licence on the Thailand to UK chain, why GACP certification alone does not put flower on a UK shelf, and how the UK requirements compare with Germany’s and Australia’s.
This is general information for licensed businesses, not legal, regulatory or investment advice. Import, manufacture and supply decisions in the United Kingdom sit with the Medicines and Healthcare products Regulatory Agency (MHRA), the Home Office Drugs and Firearms Licensing Unit, and the licensed UK importer or manufacturer. Requirements change: confirm the current position for your own consignment before contracting.
The UK market in numbers
Three figures frame why UK supply is worth understanding. Import volumes come from Home Office data released under Freedom of Information in April 2026; patient and product counts come from the Prohibition Partners UK Medical Cannabis Market Update 2026, published June 2026.
The FOI figures cover dried cannabis flower preparations supplied as unlicensed specials. They exclude extracts, active pharmaceutical ingredients and imports from the Crown Dependencies. Almost all UK patients are treated privately rather than through the NHS.
Why there is no direct lane
The single most important structural fact for any non-UK cultivator: a UK patient receives cannabis flower as an unlicensed medicinal product, a “special”, supplied under Regulation 167 of the Human Medicines Regulations 2012 against a prescription from a clinician on the GMC Specialist Register. Nothing about that route lets a farm ship to a pharmacy.
Everything turns on where the flower comes from. Imports from countries treated as approved for import, in practice the EEA states, can move on a wholesale dealer’s licence. Thailand is a third country, so it sits on the other side of that line: the UK importer must hold a Manufacturer’s “Specials” Licence granted by the MHRA that specifically authorises import. That licence, not the farm’s certification, is what makes a Thai-origin consignment lawful in the UK.
Read plainly: the question a UK buyer is really asking a Thai farm is not “can you export?” It is “can my quality system rely on your paperwork?” The regulatory burden sits with the UK licence holder. The farm’s job is to make that burden carryable.
Who holds what on the Thailand to UK chain
Six separate authorisations sit between a Thai flowering room and a UK prescription. They are held by different parties, and no single party can substitute for another.
| Authorisation | Held by | Scope |
|---|---|---|
| Thai controlled-herb export licence | The Thai exporter | Under Ministerial Regulation (No. 2) B.E. 2569, in force since 30 April 2026, alongside DTAM GACP certification for the flower being exported |
| MHRA Manufacturer’s “Specials” Licence authorising import | The UK importer | The core licence for third-country origin. Requires named quality controller and production manager, and operation to GMP |
| MHRA notification | The UK importer | At least 28 days before import, giving product name, manufacturer name and address, each active constituent, quantity and supplier address. The MHRA may object or attach conditions |
| Home Office import licence | The UK importer | Single use Issued per individual shipment, valid three months, normally processed in ten working days. Actual shipped quantities must be endorsed online afterwards |
| GMP certification of the site of manufacture | The GMP manufacturer | Overseas manufacturing sites must meet GMP standards and are subject to MHRA inspection |
| Certificate of analysis | Origin, then release testing | Per batch. Cannabinoid assay, microbial quality, heavy metals, pesticides |
A cultivation-stage supplier holds exactly one row of this table. That is the point: the chain is designed so that no farm carries UK market-release responsibility, and no importer has to take a farm’s word for quality.
GACP is the input standard. GMP is the gate.
This is where most origin conversations go wrong. GACP governs how a plant is grown, harvested and handled at the farm. GMP governs pharmaceutical manufacture and market release. They are sequential, not alternative, and a GACP certificate does not become a GMP certificate by crossing a border.
For a Thai farm, that has one practical consequence worth stating bluntly: GACP certification alone does not put flower on a UK shelf. It qualifies the flower as an input that a GMP-licensed manufacturer can take into its own quality system. The commercial question is therefore how much rework that manufacturer has to do, and rework is decided by documentation quality at origin.
What changed in June 2026, and why it favours on-farm drying
On 8 June 2026 the Hessian State Office for Health and Care (HLfGP) issued guidance targeting what it called GMP washing: the practice of importing third-country GACP flower and treating downstream EU processing as though it cured any upstream gap.
The guidance treats drying under controlled conditions as a GMP-critical manufacturing step, because it materially affects product quality. Its practical effect is that cannabis flower released as medicine in Hesse must be dried and trimmed where the plants were harvested, unless a producer can prove beyond doubt that splitting or deferring drying causes no loss of quality. The authority stated it knows of no process that has demonstrably met that bar.
Why this matters beyond Hesse. This is a single German state authority, not a UK rule and not federal German law, so it does not bind a UK importer. But it signals the direction of travel across European supply chains, and it moves the burden toward origin-side due diligence. A farm that dries and documents on site is positioned for that direction. A farm that ships wet or part-dried material for finishing elsewhere is exposed to it.
UK, Germany and Australia compared
Buyers evaluating a Thai origin usually hold more than one destination market. The requirements differ enough that a supplier fit for one is not automatically fit for another. This table compares the three routes Solar Farm is asked about most.
| Requirement | United Kingdom | Germany | Australia (starting material) |
|---|---|---|---|
| Status of the flower | Unlicensed “special” under Reg 167, Human Medicines Regulations 2012 | Medicinal product under the AMG, framework set by MedCanG since 1 April 2024 | Starting material for further manufacture, not patient-ready |
| Importer’s core licence | MHRA Manufacturer’s “Specials” Licence authorising import | Import permit under s 4 MedCanG, plus wholesale licence under s 52a AMG and narcotics licence under s 3 BtMG | ODC import licence, held annually |
| Per-consignment authority | Single-use Home Office import licence, valid three months | Per import BfArM permit under s 11 BtMG | Per consignment ODC import permit |
| Advance notification | 28 days to the MHRA | Handled through the per-import permit | Handled through the permit application |
| Standard that gates market entry | GMP at the site of manufacture. GACP at cultivation | EU-GMP, plus the Cannabisblüten monograph in the German Pharmacopoeia. GACP at cultivation | Country-GMP list does not apply under TGO 93 s 13(1). GACP at cultivation |
| Does Thai origin need a special route? | Yes. Third country, so the Specials-licence import route applies | No country list. EU-GMP is the gate, reached via a certified site or an EU processor | No. Origin lists govern finished product, not starting material |
| Biosecurity as a separate gate | Not a distinct gate | Not a distinct gate | Yes DAFF and BICON. Irradiation at 1 kGy or higher releases on documentation |
| Where drying must happen | Not separately specified | In Hesse, at the place of harvest unless no quality loss is proven (HLfGP, 8 June 2026) | At origin, under documented GACP SOPs |
Positions are current as at August 2026 and are administered by the MHRA and Home Office in the United Kingdom, BfArM and the state authorities in Germany, and the TGA, ODC and DAFF in Australia. Any of them can change. For the full mechanics of the other two routes, see our Thailand to Germany and the EU guide and our Thailand to Australia starting-material pathway.
The strategic reading for a UK buyer
UK supply is concentrated. Canadian producers shipped the largest single share of 2025 volume, and the historic pattern routed Canadian flower through Spanish and Portuguese processing before it reached the UK. That pattern is now shifting as Canadian producers process in their own EU-GMP facilities and ship in bulk directly.
What that leaves is a market growing faster than its supplier base has diversified, in which origin due diligence is becoming the binding constraint rather than volume. For a UK importer or a GMP manufacturer serving one, the question worth asking of any origin is narrow: will this farm’s records survive being pulled into my quality system, and can I evidence the chain of custody back to the room the plant grew in?
What to ask a Thai supplier before contracting
1. Certification, with audit evidence behind it. Thai GACP under the Ministry of Public Health and the Department of Thai Traditional and Alternative Medicine (MOPH/DTAM), and EU-GACP compliance. Ask for the evidence, not the claim.
2. A current Thai export licence. Under the controlled-herb framework in force since 30 April 2026. Verify it covers the material and the period.
3. An independent third-party certificate of analysis on every batch. Not one flagship lot. Cannabinoid assay, microbial quality, heavy metals and pesticides.
4. Documented on-site drying and curing. Recorded against SOPs at origin, with the parameters retained. This is the point the Hessian guidance turns on.
5. Lot-level traceability. Each lot traceable to its room, cycle and inputs, so a continuous record survives into the GMP manufacturer’s file.
6. A stated position on rework. Ask what the supplier does when a batch fails release testing, and who bears it. The answer tells you more than any certificate.
Where Solar Farm fits
Solar Farm is an indoor, cultivation-stage medical cannabis supplier in Pathum Thani, Thailand, growing across 22 flowering rooms in a 5,800 m² facility. We are a cultivation-stage supplier, not a GMP manufacturer and not a UK importer, and this guide is written on that basis.
For a UK importer holding a Manufacturer’s “Specials” Licence, or a GMP manufacturer preparing material for one, what we can put on paper maps onto the checklist above:
- Thai GACP certification (MOPH/DTAM) and EU-GACP compliance.
- An independent third-party certificate of analysis on every batch, covering cannabinoid assay, microbial quality, heavy metals and pesticides.
- Documented on-site drying and curing under GACP SOPs, with parameters recorded and retained.
- Lot-level traceability to room, cycle and inputs across 22 flowering rooms.
- Year-round indoor cultivation, giving batch-to-batch consistency rather than a seasonal window.
- Export activity licensed under the current Thai controlled-herb framework. Our Thailand cannabis regulation tracker follows the licensing changes affecting any Thai supplier.
The division of labour is the same one that already carries Thai GACP flower to licensed importers in Germany and the wider EU. We supply consistent, audit-ready cultivation-stage flower with complete batch documentation. The GMP manufacturer builds on it. The licence holder carries market release.
Licensed UK importers, GMP manufacturers and their sourcing partners can request our supplier dossier: certifications, audit summary, sample COAs and batch-record structure.
We work with licensed businesses only, and verify counterparties first. For licensed businesses only.
Frequently Asked Questions
Can Thai medical cannabis be exported to the United Kingdom?
Is GACP certification enough to supply the UK market?
What licences does a UK importer of Thai cannabis flower need?
How does the UK import route differ from Germany’s?
Does cannabis flower have to be dried at the farm where it was grown?
How large is the UK medical cannabis import market?
Changelog
August 10, 2026. Page published: the Thailand to United Kingdom import route for licensed buyers, covering the unlicensed specials framework under Regulation 167 of the Human Medicines Regulations 2012; the six authorisations on the chain and who holds each; the distinction between GACP as input standard and GMP as market gate; the Hessian HLfGP guidance of 8 June 2026 on drying as a GMP-critical step; a destination-market comparison of UK, German and Australian requirements; and a supplier due-diligence checklist. Market figures from Home Office FOI data released April 2026 and the Prohibition Partners UK Medical Cannabis Market Update 2026. General information for licensed businesses, not legal advice; positions current as at August 2026 and subject to change.